Journal
JOURNAL OF IMMUNOTHERAPY
Volume 43, Issue 2, Pages 48-52Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CJI.0000000000000304
Keywords
transferrin receptor 1; multiple myeloma; antibody effector functions; antibody therapy
Categories
Funding
- National Institutes of Health (NIH) [R01CA196266, R01CA196266-01A1:S1, R01CA196266-03, R01CA196266-04S1]
- UCLA AIDS Institute
- UCLA Center for AIDS Research NIH Grant [P30AI028697]
- NIH [P30AI028697, P30CA016042]
- JCCC
- David Geffen School of Medicine at UCLA
- UCLA Chancellor's Office
- UCLA Vice Chancellor's Office of Research
Ask authors/readers for more resources
The transferrin receptor 1 (TfR1) is a meaningful target for antibody-based cancer therapy given its overexpression on malignant cells and its central role in cancer pathology. We previously developed a mouse/human chimeric IgG3 targeting human TfR1 (ch128.1), which exhibits significant antitumor activity against multiple myeloma (MM) in xenograft models of SCID-Beige mice bearing disseminated ARH-77 or KMS-11 tumors. This activity is observed in early and late disease stages of disseminated KMS-11 tumors and, in this model, the mechanism of antitumor activity is Fc-mediated, involving macrophages. As human IgG1 is the isotype of choice for therapeutic antibodies targeting malignant cells and has several advantages compared with IgG3, including established manufacturability, we now developed an IgG1 version of ch128.1. A single dose of ch128.1/IgG1 shows significant antitumor activity, not only against early and late stages of disseminated KMS-11 tumors (Asian origin) but also against these stages of disseminated disease following injection of human MM cells MM.1S (African American origin) or its variant that is resistant to dexamethasone MM.1R. Treatment with the Fc mutant version of ch128.1/IgG1 (L234A/L235A/P329S) with impaired effector functions fails to confer protection against MM.1S and MM.1R tumors, indicating a crucial role of the Fc fragment in the antitumor activity, similar to its IgG3 counterpart. In fact, we found that ch128.1/IgG1, but not the mutant, elicits antibody-dependent cell-mediated cytotoxicity and antibody-dependent cell-mediated phagocytosis in the presence of murine bone marrow-derived macrophages. Our results suggest that ch128.1/IgG1 is a promising therapeutic against human B-cell malignancies such as MM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available